Legal experts at Walker Morris advised life sciences company Avacta Group plc, the developer of Affimer® biotherapeutics and reagents, as it entered into an exclusive distribution agreement with Medusa19 Limited for direct-to-consumer sales of a saliva-based rapid test for the COVID-19 antigen.
Wetherby based Avacta has partnered with Cytiva to develop the innovative new antigen test to indicate whether individuals are infected with COVID-19, providing results within minutes. Walker Morris advised the Group on its exclusive distribution agreement with Medusa19 for the supply of the COVID-19 rapid test globally, subject to the necessary regulatory approvals.
Avacta’s innovation is in response to the global demand for rapid antigen tests, which will be crucial in getting millions of healthy, non-contagious people back to work as countries around the world exit lockdown.
Avacta Group Plc (LON:AVCT) offers reagents and therapeutics based on Affimer technology for diagnostic and research applications in the United Kingdom. The company’s custom Affimer products are also used in drugs and biomarkers discovery in biotech research and development.